Revenue segments as reported by the company.

Diagnostics

Drug Development

Intercompany eliminations and other

Biopharma Laboratory Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative expenses

Amortization of intangibles and other assets

Goodwill and other asset impairments

Restructuring and other charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Labcorp Holdings Inc

Laboratory Corp. of America Holdings operates as a life sciences company, which engages in the provision of vital information to help health professionals make clear and confident decisions. It operates through the Drug Development and Diagnostics segments. The Drug Development segment consists of lead optimization, preclinical safety assessment, analytical services, clinical trials, central laboratories, biomarkers, and companion diagnostics, market access, and technology solutions. The Diagnostics segment includes primary care, women's health, specialty medicine, oncology, ACOs, and hospitals and health systems. The company was founded in 1971 and is headquartered in Burlington, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Labcorp posts strong Q4 results, eyes growth amid strategic moves

Labcorp's Q4 performance reflects resilience and growth potential in Diagnostics and Drug Development
Strategic initiatives and spinoff plans position Labcorp for future success and market leadership
Challenges in cost management and revenue growth require focused strategies for sustainable growth
Opportunities lie in capital deployment, market expansion, and operational enhancements for Labcorp

Labcorp reports strong Q1 results, eyes growth amid challenges

Labcorp's Q1 2023 performance was strong, driven by Diagnostics base business revenue growth and strategic initiatives.
While facing challenges like margin constraints and revenue declines in Drug Development, Labcorp is focusing on sustained growth and market opportunities.
The company's emphasis on digital health, upcoming Investor Days, and robust M&A pipeline showcase a proactive approach to future growth.
Labcorp's cautious optimism for SALSA approval and continued advocacy for legislation position it well for potential impacts and future developments.

Labcorp reports robust Q2 earnings, eyes global expansion opportunities

Labcorp's Q2 performance was strong, with revenue growth and strategic initiatives driving positive results.
Challenges such as supply constraints and margin expectations were addressed, with a focus on capital allocation and growth opportunities.
The company remains optimistic about future prospects, with expansion plans, enhanced disclosures, and consistent guidance for segments.
Investor Day scheduled for September to provide more insights, reflecting Labcorp's commitment to transparency and growth.

Labcorp reports robust Q3 earnings, eyes growth amid regulatory challenges

Labcorp's Q3 performance was strong, with a focus on revenue growth, strategic partnerships, and new test introductions. Despite challenges from regulatory impacts, the company remains optimistic about driving substantial shareholder value through growth opportunities and cost-saving initiatives.

LabCorp reports robust Q4 earnings, eyes growth in strategic areas

LabCorp's Q4 call showcased strong financials, strategic partnerships, and innovative offerings. Challenges include pricing issues in Biopharma and COVID impacts on Diagnostics. Opportunities for growth through capital allocation and focus on larger pharma in Biopharma.

LabCorp reports robust Q1 earnings, eyes margin improvement in 2024

LabCorp's Q1 2024 earnings call highlighted strong financial performance, strategic acquisitions, and plans for margin improvement. Despite challenges in certain business areas, the company remains focused on profitable growth and innovation in specialty testing.

Labcorp reports robust Q2 earnings, eyes growth through innovation

Labcorp's Q2 2024 earnings reflect a strong performance, marked by revenue growth, strategic acquisitions, and innovation in healthcare solutions.
While facing challenges in certain segments, Labcorp's focus on expansion, new tests, and digital solutions positions it well for future growth and market leadership.
With a clear outlook for growth and a commitment to advancing healthcare, Labcorp remains a key player in the diagnostics and biopharma laboratory services industry.

Labcorp reports robust Q3 earnings, eyes growth through strategic partnerships

Labcorp's Q3 2024 performance reflects strong revenue growth and profitability, driven by Diagnostics and Biopharma services.
Despite challenges such as regulatory delays, the company remains focused on strategic growth initiatives and operational efficiency.
With a positive outlook for continued growth, Labcorp's emphasis on partnerships, innovation, and cost-saving measures bodes well for its long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.

BURLINGTON, N.C. , Sept. 16, 2024 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH) (Labcorp) announced today that its wholly owned subsidiary, Laboratory Corporation of America Holdings (LCAH), has priced its offering of $2,000,000,000 in senior notes (the Offering).

LABCORP PRICES $650,000,000 IN 4.350% SENIOR NOTES DUE 2030, $500,000,000 IN 4.550% SENIOR NOTES DUE 2032 AND $850,000,000 IN 4.800% SENIOR NOTES DUE 2034

OPKO Health

Enhances Labcorp's laboratory services network and expands access to its clinical services  BURLINGTON, N.C. and MIAMI , Sept.

Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health

LH is well-placed for long-term success in Cell & Gene Therapy, expanding into the consumer market and international growth through the specialty testing and biopharma business.

Labcorp Stock Gains From Market Expansion Efforts Amid Macro Woes

Labcorp has reached an agreement to purchase select outreach laboratory services from Ballad Health.

LH Stock Expected to Gain From the Ballad Health Acquisition Deal

SAN FRANCISCO--(BUSINESS WIRE)--Xcell Biosciences Inc. (Xcellbio), an instrumentation company focused on cell and gene therapy applications, today announced it has advanced its collaboration with Labcorp with the installation of a new AVATAR™ Foundry system at the healthcare company's Ann Arbor, Michigan site. This installation, part of the beta access program for Xcellbio's latest instrument, allows scientists at Labcorp to extend the potency benefits observed in small-scale workflows on the p.

Xcell Biosciences Advances Labcorp Collaboration with Novel Platform for Automated Cell and Gene Therapy Manufacturing

BURLINGTON, N.C. , Sept. 3, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that members of the executive management team will participate in a presentation at the Baird 2024 Global Healthcare Conference on Tuesday, September 10, at 3:10 p.m.

Labcorp to Speak at the Baird 2024 Global Healthcare Conference

Diagnostics firm Labcorp said it is processing approximately 500 mpox tests a month but have the capacity to process approximately 25,000 per month.

Labcorp says it could ramp up mpox testing capacity

Labcorp's (LH) slew of partnerships and acquisitions and robust efforts in high-growth areas bode well.

Should You Hold Labcorp (LH) Stock in Your Portfolio Now?

Labcorp's (LH) Biopharma Laboratory Services business is benefiting from collaborations with leading pharmaceutical and biotechnology companies.

Labcorp (LH) Gains From New Collaborations Amid FX Issues

Invitae Corp

Extends Labcorp's leadership in genetic testing solutions for oncology and select rare diseases BURLINGTON, N.C. , Aug. 5, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the completion of its acquisition of select assets of Invitae (OTC:NVTAQ), a leading medical genetics company.

Labcorp Finalizes Acquisition of Select Assets of Invitae

C.H. Robinson Worldwide

Clorox

Kellogg

Teleflex

August has already made it a cruel summer for stocks.

5 Stocks That Have Bucked August's Selloff, and How They've Done It

Labcorp has broken out in strong volume after second-quarter results and a bigger stock buyback.

Health Care Stock Soars Past Buy Point After Boosting Buyback

Labcorp Holdings Inc LH reported better-than-expected second-quarter financial results and raised its FY24 revenue guidance above estimates on Thursday.

LabCorp Analysts Boost Their Forecasts After Better-Than-Expected Earnings

PGDx elio™ plasma focus Dx is the industry's first and only kitted, pan-solid tumor liquid biopsy test that enables tumor mutation profiling – all from a simple blood draw BURLINGTON, N.C., Aug. 2, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it has received De Novo marketing authorization from the U.S. Food and Drug Administration (FDA) for PGDx elio™ plasma focus Dx – the industry's first and only kitted, pan-solid tumor liquid biopsy test.

Labcorp Receives FDA De Novo Marketing Authorization for PGDx elio™ plasma focus Dx

Labcorp (LH) beats on earnings and revenues in the second quarter, entering the second half of 2024 with robust momentum.

Labcorp (LH) Q2 Earnings Surpass Estimates (revised)

Labcorp Holdings Inc (NYSE:LH ) Q2 2024 Results Conference Call August 1, 2024 9:00 AM ET Company Participants Christin O'Donnell - Vice President of Investor Relations Adam Schechter - Chairman, President & Chief Executive Officer Glenn Eisenberg - Executive Vice President, Chief Financial Officer Conference Call Participants Michael Cherny - Leerink Partners Andrew Brackmann - William Blair Eric Coldwell - Baird Elizabeth Anderson - Evercore ISI Jack Meehan - Nephron Research Kevin Caliendo – UBS Lisa Gill - JPMorgan Erin Wright - Morgan Stanley John Kim - Bank of America Stephanie Davis - Barclays Patrick Donnelly - Citi Operator Good day, and thank you for standing by. Welcome to the Labcorp Holdings Inc. Second Quarter 2024 Conference Call.

Labcorp Holdings Inc (LH) Q2 2024 Earnings Call Transcript

Thursday, Laboratory Corp A reported second-quarter 2024 adjusted EPS of $3.94, up from $3.42 a year ago, beating the consensus of $3.78.

LabCorp's Stock Soars After Q2 Performance, Analyst Highlights Strong Position In Healthcare Sector

Labcorp (LH) Q2 Earnings Surpass Estimates, Margins Increase

The headline numbers for Labcorp (LH) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Compared to Estimates, Labcorp (LH) Q2 Earnings: A Look at Key Metrics

Labcorp (LH) came out with quarterly earnings of $3.94 per share, beating the Zacks Consensus Estimate of $3.78 per share. This compares to earnings of $3.42 per share a year ago.

Labcorp (LH) Beats Q2 Earnings and Revenue Estimates

Labcorp beat Wall Street expectations for second-quarter profit and revenue on Thursday on strong demand for its diagnostic tests, and raised its sales growth forecast for the year.

Labcorp beats Q2 profit and revenue estimates on demand for health tests

Updates Full-Year Guidance Results from Continuing Operations for second quarter 2024 versus last year: Revenue: $3.22 billion versus $3.03 billion Diluted EPS: $2.43 versus $1.74 Adjusted EPS: $3.94 versus $3.42 Free Cash Flow: $432.9 million versus $58.2 million Updated Full-Year 2024 Guidance: Revenue range of 6.4% to 7.5%, includes Invitae impact of ~1.0% Adjusted EPS range of $14.30 to $14.90, includes Invitae dilution of ~$0.40 Free Cash Flow of $0.85 billion to $1.00 billion, includes Invitae cash usage of ~$150 million Share repurchase authorization increased by $1.0 billion to $1.4 billion Launched important new tests in specialty testing areas Introduced Labcorp Global Trial Connect, a suite of central laboratory solutions aimed to accelerate clinical trials BURLINGTON, N.C. , Aug. 1, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the second quarter ended June 30, 2024 and updated full-year guidance.

Labcorp Announces 2024 Second Quarter Results

Bio-Rad Laboratories

Bruker

Here is a sneak peek into how four MedTech companies, LH, BIO, TFX and BRKR, are expected to fare in their second-quarter results, slated to be released tomorrow.

What's in Store for These 4 MedTech Stocks in Q2 Earnings?

Labcorp Expands Collaboration with Ultima Genomics to Advance Whole Genome Sequencing Applications and Oncology Testing Capabilities

Labcorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for Labcorp Holdings Inc Stock (LH)